Voltar
Artigo Revisado por pares
BIBTEX RIS

A Prospective Randomized Trial of Esomeprazole- versus Pantoprazole-Based Triple Therapy for Helicobacter pylori Eradication

2005; Lippincott Williams & Wilkins; Volume: 100; Issue: 11 Linguagem: Inglês

10.1111/j.1572-0241.2005.00264.x

ISSN

1572-0241

Autores

Ping‐I Hsu, Kwok‐Hung Lai, Chiun‐Ku Lin, Wen‐Chi Chen, Hsien‐Chung Yu, Jin‐Shiung Cheng, Feng‐Woei Tsay, Chung-Jen Wu, Gin‐Ho Lo, Hui‐Hwa Tseng, Yoshio Yamaoka, Jinliang Chen, Gin‐Ho Lo,

Tópico(s)

Gastric Cancer Management and Outcomes

Resumo

OBJECTIVE This prospective, randomized, controlled, head-to-head study was conducted to compare the efficacies of esomeprazole- and pantoprazole-based triple therapies for Helicobacter pylori eradication. METHODS From January 2002 to October 2003, 200 H. pylori-infected patients were randomly assigned to undergo twice daily treatment with esomeprazole 40 mg (n = 100) or pantoprazole 40 mg (n = 100) combined with clarithromycin 500 mg and amoxicillin 1 g for 1 wk (ECA and PCA groups, respectively). Follow-up endoscopy was performed at 8 wks after the end of treatment to assess the treatment response. RESULTS Intention-to-treat analysis demonstrated a significantly higher eradication rate for the ECA group than for the PCA group (94% vs 82%, respectively, p = 0.009). Per-protocol analysis also showed similar results (97% vs 84%, p = 0.003). Both groups had similar frequencies of adverse events (15% vs 24%) and drug compliance (97% vs 96%). Multivariate analysis disclosed that the use of esomeprazole (OR: 1.56, 95% CI, 1.11–2.19) and good compliance 7.39 (95% CI, 1.27–42.95) were independent predictors of treatment success. Alcohol drinking was an independent predictor of eradication failure (OR: 0.18; 95% CI, 0.06–0.54). CONCLUSION Esomeprazole-based triple therapy demonstrated a higher eradication rate than pantoprazole-based regimen. The differences in eradiation efficacies between the two study groups may be related to the more powerful acid inhibition effect and stronger anti-H. pylori activity of esomeprazole compared to pantoprazole.

Referência(s)